End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.89 CNY | -0.90% | +7.27% | -2.18% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 53% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 49.45 times its estimated earnings per share for the ongoing year.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.18% | 553M | - | ||
+5.18% | 1.75B | B+ | ||
+5.41% | 979M | D+ | ||
+9.13% | 966M | - | ||
+64.31% | 752M | - | - | |
-2.47% | 692M | - | - | |
+29.53% | 600M | B- | ||
+15.68% | 499M | - | ||
-0.72% | 424M | - | D+ | |
-22.73% | 405M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 300758 Stock
- Ratings Anshan Hifichem Co., Ltd.